About
Raymond C. Stevens, Ph.D., has served as Chief Executive Officer, and as a director, of Structure Therapeutics (formerly known as ShouTi), a biotechnology company, since May 2019. He has also launched multiple biotechnology companies focused on drug discovery.
Professor Stevens is considered among the world's most influential biomedical scientists in molecular research. A pioneer in human cellular behavior research, he has been involved in the creation of therapeutic molecules that led to breakthrough drugs targeting influenza, childhood diseases, neuromuscular disorders and diabetes. His extensive experience living and working in China is also valuable to Danaher given China's strategic significance to its business.
Roles
Danaher Corp.
Independent Director · Current role
2017–present
University of Southern California
Provost Professor of Biological Sciences and Chemistry; Founder and Director of The Bridge Institute · A private research university.
July 2014 – August 2021
The Scripps Research Institute
Professor of Molecular Biology and Chemistry · A non-profit research organization.
1999 – July 2014
Receptos
Founder · Developed Zeposia, a GPCR agonist approved in 2020 for multiple sclerosis and 2021 for ulcerative colitis; per Danaher's official bio.
—
Syrrx
Founder · A platform company acquired for clinical assets; per the official bio.
—
RuiYi
Founder · A platform company acquired for clinical assets; per the official bio.
—
External Roles
Structure Therapeutics
Chief Executive Officer and Director
May 2019 – present
Director Compensation
FY 2025
Fees earned or paid in cash
Not disclosed